Overview Markets Watchlist

© 2026 IR SuperintelMethodology Contact

Tenax Therapeutics Inc

CUSIP: 88032L955 | 3 institutional holders

Quarters

Q3 2026 Q2 2026

Compare Detailed Historical Funds Options Short Interest 13D/13G Peers Targeting Trading Summary Profile